Status and phase
Conditions
Treatments
About
The primary objective of this study is to evaluate the effect of rilonacept, added to standard therapy and compared with standard therapy alone, on improvement in myocardial inflammation in subjects with cardiac sarcoidosis after 24 weeks of therapy.
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Inclusion Criteria:
Able to comprehend and willing to sign an ICF and to abide by the study restrictions and requirements
Age ≥ 18 years and ≤ 80 years
Female subjects must be:
Male subjects must have documented vasectomy or must use double barrier methods of contraception (such as condom plus diaphragm or diaphragm plus spermicide or condom plus spermicide) or use condoms plus hormonal contraceptives or condoms plus IUD with their female partners of childbearing potential from randomization to 3 months after the last dose of study drug administration. Male subjects must agree to refrain from donating sperm during this time period.
Has completed recommended vaccinations per current guidelines prior to first dose of study drug
Cardiac Inclusion Criteria:
Has a diagnosis of cardiac sarcoidosis by the Heart Rhythm Society (HRS) expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis, or the Japanese Circulation Society 2016 Guideline on diagnosis and treatment of cardiac sarcoidosis (Terasaki 2019)
Three or more segments of active FDG uptake on PET scan within 8 weeks of randomization, despite standard therapy
Willing to wear an ambulatory cardiac rhythm monitor at the specified timepoints
Exclusion Criteria
Unable or unwilling to provide informed consent
Weight >380 pounds (172 kilograms)
Women who are pregnant or lactating or women of childbearing age who refuse to use a highly effective and medically acceptable form of contraception throughout the study
Planned to initiate TNF-α antagonist therapy over the course of the study.
Known claustrophobia, or difficulty completing prior PET scan procedure(s)
Left ventricular end-systolic diameter (LVESD) > 60 mm on echocardiogram
Other systemic immune disorder(s) or other disorder(s) that require treatment with immunomodulators or immunosuppressants
Has received, or is scheduled to receive after randomization, mechanical circulatory support
Congenital, valvular, and/or coronary artery disease that could explain the severity of cardiac dysfunction
Known hypersensitivity to Rilonacept or to any of its excipients
Meets the following TB criteria:
Use of the following immunosuppressive or immunomodulatory therapies (see also Section 5.6 "Prior and Concomitant Therapy") within the timeframe prior to randomization as defined below for each drug class or category:
Received any investigational product within 30 days or 5 half-lives (if the half-life is known) of an investigational product (whichever is longer) prior to first dose of study drug
Concurrent enrollment in another clinical study, with the exception of observational studies
Uncontrolled hypertension (systolic blood pressure >170 mmHg and diastolic blood pressure >110 mmHg
Uncontrolled thyroid disease (serum TSH < 0.1 mU/L or > 10 mU/L)
Uncontrolled diabetes mellitus (serum glucose > 180 mg/dL fasting or HbA1c >8%)
Estimated glomerular filtration rate (eGFR) (eGFR) <30mL/min
Major surgery within 8 weeks prior to screening or planned major surgery within 6 months after first dose of study drug.
Transplanted organs (except corneal transplant performed more than 3 months prior to first dose of study drug).
Severe active, recurrent, or chronic infection (per PI discretion), or any episode of infection requiring hospitalization or treatment with a course of IV antibiotics within 12 weeks before screening. Subjects with a history of severe opportunistic infection (per PI discretion) are also excluded from the study.
High risk of infection (e.g., history of hereditary or acquired immune deficiency disorder), a history of an infected joint prosthesis at any time with that prosthesis still in situ, leg ulcers, indwelling urinary catheter, or persistent or recurrent chest infections.
Chronic active HBV infection, defined as:
Presence of symptoms indicative of COVID-19 infection (per PI discretion), unless a PCR test for COVID-19 has been reported as negative within the previous 7 days or is acquired prior to randomization.
History of cancer within the last 5 years from screening, except for basal and squamous cell carcinoma of the skin or in situ carcinoma of the cervix treated and considered cured.
Has screening laboratory test results meeting any of the following criteria:
Any condition that, in the opinion of the investigator, could interfere with evaluation of the investigational product or interpretation of subject safety or confound the results of the study
Primary purpose
Allocation
Interventional model
Masking
60 participants in 2 patient groups
Loading...
Central trial contact
Lezlie Peterson, R.N.
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal